Promisia Healthcare Limited logo

Investor Presentation and Capital Raise announcement

Capital Raise2 July 2024PHLHealthcare

Market Announcement
2 July 2024


INVESTOR PRESENTATION AND CAPITAL RAISE ANNOUNCEMENT


As per the announcement of 25 June 2024, Promisia Healthcare Limited (Promisia) (NZX: PHL) will be

undertaking a capital raise in July 2024 by way of a combination of placements and a share purchase

plan offered to all shareholders (Offer).

Promisia’s Investor Presentation

As part of this announcement, Promisia are pleased to share with the market a copy of Promisia’s

investor presentation. This presentation has a strong focus on Promisia’s strategic outlook and

provides comprehensive updates on the following:

• Promisia’s existing portfolio, operations and strategic objectives;

• commentary on the positive FY24 results and FY25 outlook;

• details around the mechanics of the Cromwell acquisition and the financial impact; and

• Promisia’s growth objectives and value opportunities.


The Offer

The Board has resolved to undertake the Offer at $0.001 per share with a minimum of $3 million to

be raised. The Board has discretion to accept oversubscriptions of up to $1 million.

In addition, Promisia will offer one warrant for every share acquired under the Offer for no

additional consideration. Each warrant gives shareholders the right, but not the obligation, to

subscribe for one additional ordinary share in PHL on or before the expiry date for an exercise price

of $0.002. The expiry date of the warrants is 24 March 2027. Application has been made to NZX for

quotation of the warrants on the NZX Main Board and all the requirements of NZX that can be

complied with on or before the date of this announcement have been duly complied with. However,

NZX accepts no responsibility for any statement in this announcement.

The share purchase plan is intended to open on Thursday 11 July 2024 with a record date of

Wednesday 10 July 2024. Eligible shareholders will be able to apply for NZ$50,000 of shares at an

issue price of NZ$0.001, with the ability to over or under subscribe.

Shares issued under the placement and SPP will rank equally and be of the same class as the shares

quoted on the NZX Main Board.

The proposed timetable of the share purchase plan is below:





Event Date

SPP Ex date Tuesday 9 July

Record Date for SPP Wednesday 10 July (5pm)

SPP Opens Thursday 11 July

SPP closes Monday 29 July (5pm)

Settlement and allotment of SPP Monday 5 August



The dates set out in the table above are subject to change and are indicative only.

Authority for this announcement:

Rhonda Sherriff, Chair, Promisia Healthcare Limited

For more information, please contact:

Francisco Rodriguez Ferrere, General Manager – Finance, Promisia Healthcare Limited

Phone: +64 21 245 1801 or email: Francisco.rf@promisia.co.nz

About Promisia Healthcare

Promisia is a New Zealand based aged care and retirement living provider, with a focus on delivering

quality personalised care. Our aim is to be the aged care provider of choice in our communities. Our

facilities are located in well-established and well serviced towns and metropolitan areas. Our goal is

to profitably grow our business in a sustainable manner, delivering quality care to our residents,

peace of mind to their families and whanau, and excellent value to our villages, community and

shareholders. Promisia is listed on the NZX (NZX: PHL). http://www.promisia.co.nz.

---

Corporate Action Notice
(Other than for a Distribution)

Updated June 2024

Page 1 of 2


Section 1: Issuer information

Name of issuer Promisia Healthcare Limited

Class of Financial Product Ordinary shares

NZX ticker code PHL

ISIN (If unknown, check on NZX

website)

NZPRPE0001S5

Name of Registry MUFG Pension & Market Services (formerly Link

Market Services)

Type of corporate action

(Please mark with an X in the relevant

box/es)

Share Purchase

Plan/retail offer

X Renounceable

Rights issue or

Accelerated

Offer


Capital

reconstruction

Non-

Renounceable

Rights issue or

Accelerated

Offer


Call Bonus issue

Placement

Record date 5pm, Wednesday 10 July 2024

Ex Date (one business day before the

Record Date)

9 July 2024

Currency NZD

Section 6: Share Purchase Plans/retail offer

Number of Equity Securities to be

issued


Up to 4,000,000,000 ordinary shares in PHL (in

accordance with NZX Listing Rules 4.3.1(c) and 4.5.1)

Minimum application amount (if

any)

N/A

Maximum application amount per

Equity Security holder

$50,000.00 (with the ability to accept oversubscriptions)

Subscription price per Equity

Security

$0.001

Scaling reference date

1

By reference to holdings at Record Date



2 of 2

Closing date 5pm, 29 July 2024

Allotment date 5 August 2024

Section 9: Authority for this announcement

Name of person authorised to make this

announcement

Rhonda Sherriff, Chair

Contact person for this announcement Francisco Rodriguez Ferrere, General Manager

Contact phone number 021 245 1801

Contact email address Francisco.rf@promisia.co.nz

Date of release through MAP 2/07/2024

---

1
Promisia Healthcare

Investor presentation

July 2024

2
Disclaimer

Promisia Healthcare Limited (Promisia) is raising capital and this presentation (Presentation) is provided in relation to the opportunity to invest in

Promisia’s capital raising (Opportunity).

About this Presentation

Although reasonable care has been taken in the preparation of this Presentation, no information has been independently verified by any person. No

representation or warranty, express or implied, is made nor is any responsibility accepted with respect to the completeness or accuracy of this

Presentation.

Forward Looking Statements

This Presentation contains forward looking statements. Such statements, estimates, projections and forecasts reflect various assumptions which

may or may not prove to be correct and may be within or outside the control of Promisia. Actual results may differ materially.

Limited Liability

To the extent permitted, no person shall have any responsibility or liability arising in respect of the information contained in this Presentation or in

any way for errors or omissions in it (including by reason of negligence).

Due Diligence

This Presentation does not contain or disclose all information that may be required to evaluate the Opportunity. This Presentation may also be

amended or supplemented at any time. If an offer of financial products of Promisia financial products is made in the future, prospective investors

should conduct their own investigations, verifications and assessment of the merits of the Opportunity, identify the information that they require,

request such information from

Promisia and engage their own professional advisers to advise them on it. This Presentation alone should not form

the basis for such an investment decision.

No Recommendation

This Presentation is not an investment recommendation or investment advice to make an investment in Promisia or in the industry sectors in

which Promisia operates.

3
Contents

Group portfolio and operations Slides 4 - 8

FY24 results and FY25 outlook Slides 9 - 12

Cromwell acquisition Slides 13 - 17

Capital raise and financial position Slides 18 - 25

4
Our Current Portfolio

Promisia Healthcare has a

portfolio of four aged care

facilities, specialising in high care

needs and specialised aged care.

Our group comprises more than

400 available beds and 44

independent living villas.

All facilities are fully owned by

Promisia.

Ranfurly Manor, Feilding

Beds161

Villas38

Staff131

SiteOwned

Nelson Street, Feilding

Beds49

Villas-

Staff38

SiteOwned

Eileen Mary, Dannevirke

Beds58

Villas6

Staff45

SiteOwned

Aldwins House, Christchurch

Beds144

Villas-

Staff84

SiteOwned

5
Ranfurly Manor, Feilding

Care Facility

•79 dual (rest home & hospital) care beds

•25 specialised dementia care beds

•87% occupancy

Village & Occupational Rights Agreements

•57 apartments, providing either assisted living or

full care

•38 villas

•Villas 100% occupied, 24 available apartments

Key Financials

•$10.5m gross annualised revenue

•$3.7m EBITDA (FY24)

•March 24 valuation of $30.7m (+16% vs Mar 23)

Key strategic objective / value opportunity

•Sell down of available apartments

•Increase care occupancy to >92%

6
Care Facility

•49 Rest home level care beds

•Significant refurbishment completed in 2017

•Figure of 8 formation with two central

courtyards

•Regional demand for dementia care coupled

with its location, size and layout, makes it ideal

to transition up to 50% of the beds to

dementia level care

Key Financials

•$2.6m gross annualised revenue

•$0.7m EBITDA (FY24)

•March 24 valuation of $4.15m (+19% vs Mar 23)

Key strategic objective

•Secure certification for 20+ rest home level

dementia care beds

•Increase and maintain occupancy above 92%

Nelson Street, Feilding

7
Aldwins House, Christchurch

Care Facility

•Large scale purpose-built two-story care facility

southeast of Christchurch CBD

•Extensive refurbishment completed in 2020

•144 dual care beds, most with ensuites

•Recent certification for up to 40 YPD residents

(young people with lifelong disabilities and longer

length of stay)

•115 residents (June 2024)

Key Financials

•c.$9.5m gross annualised revenue (at 115 residents)

•$1.4m EBITDA (FY24)

•March 24 valuation of $18.1m (+13% vs Mar 23)

Key strategic objective / value opportunity

•Niche YPD care offering is a key opportunity, with

significant demand for this type of care

•Increase occupancy to >135 residents (>94%)

8
Care Facility & Village

•39 dual care beds

•19 apartments (occupational rights

agreements) providing either rest home or

hospital level care

•6 Villas (all occupied)

Key Financials

•$3.6m gross annualised revenue

•$1.0m EBITDA (FY24)

•March 24 valuation of $6.5m

Key strategic objective

•Exit in the short term, recycling capital into

future acquisitions

Eileen Mary, Dannevirke

9
Results to 31 March 2024

A solid full year result, with particularly strong

second half performance.

Impact and momentum being created by the

new leadership team is evident, with

immediate focus on:

•Increasing occupancy, including strategic

care bed repurpose (Aldwins House and

Nelson Street)

•Successful sell down of ORAs

•Focus on improving the quality of care to

meet the needs of our clients

•Ensuring appropriate financial controls and

rigour

•Staff engagement, systems and training

Operating Revenue: $26.3m(+10%)

Operating Expenses:$18.9m(+7%)

Underlying EBITDAF: $3.8m(-7%)

NPAT: $1.6m(+136%)

Total Assets: $84.3m(+18%)

Debt: $29.2m(-6%)

NTA per share:0.126c(+37%)

10
Building a stronger foundation for growth

Stronger business

Invest in our business and our people, creating

a robust scalable platform for growth, with

strong leadership and governance

Network Expansion

Grow our network through strategically located

value-accretive acquisitions, brownfield and

greenfield developments

Diverse Revenue Streams

Increase the focus on independent living

options, broaden the range of services at each

facility and increase the number of higher

acuity beds

Maximise Occupancy

Grow revenue through offering quality care to

maximise occupancy at existing and future

facilities; and repurposing beds as needed to

meet market demand

Operational and financial performance a result of our laser focus on

our four strategic pathways:

11
Growth objectives and value opportunities

Aldwins House

•Obtain certification for 40 YPD

beds (completed)

•Increase YPD resident from 15 to

40 (underway)

•Maintain occupancy levels above

135 residents (>94%)

Capital recycling

•Prepare Eileen Mary for potential sale (complete)

•Recycle proceeds from disposals into growth and value

add opportunities (underway)

Nelson Street

•Certification for 20 dementia care

beds (underway)

•Conversion of wing into specialised

dementia unit (designs complete,

light capex required)

•Lift occupancy from 80% to >92%

Ranfurly Manor

•Widen offering for apartments to

include assisted living (complete)

•Targeted care suite and assisted

living marketing (underway)

•Sell down available apartments

Cromwell acquisition

•Secure financing for acquisition of Golden View and

Ripponburn care facilities (underway)

•Integrate Cromwell facilities into wider Promisia group

(resident and staff engagement underway)

•Realise operational efficiencies (pathway completed)

Organic growth

Capital recycling and acquisitions

12
Outlook for year ending March 2025

Expect double digit earnings growth from existing operations

Operational improvements already complete or underway can

expect a positive impact on valuations

Planned acquisitions to be both materially accretive to earnings

and NTA

13
Planned Acquisition Cromwell, Central Otago

$33m being paid for two villages and

facilities adjacent to each other in

Cromwell.

Golden View

Large scale retirement village established

in 2016, with integrated care facility built

in 2022.

Ripponburn

Older care facility with additional

bungalow style villas. Significant

development potential with 2.8 hectares

of land across the site.

Provides exposure to the growing large

population in the Central Otago region,

with lower land prices than Wanaka or

Queenstown and much better availability

to care staff.

Golden View Care Facility and Village

Ripponburn Hospital and Home

14
Golden View Care Facility

and Village, Cromwell

Care Facility & Village

•60 bed care facility, comprised of:

•48 dual care bed facility

•12 bed dementia level care wing

•19 serviced apartments

•102 independent living units (1-3 bedroom villas)

•Community and recreational facilities

Occupancy

•Care facility: 97%

•Villas: 100%

Valuation (care facility and apartments)

•March 2024: $14m

15
Ripponburn Hospital and

Home, Cromwell

Care Facility & Village

•46 dual care beds

•16 villas, 2 bed units with garage

•27,935 sqm of land across the site, over 70% of

which has potential for future development

Occupancy

•Care facility: 96%

•Villas: 100%

Valuation

•March 2024: $5m

16
Cromwell Acquisition

Financial impact

Earnings accretive

•c. $10.5m of gross annualised

operating revenue

•Significant cost saving synergies

identified using Promisia’s scale and

established platform

•Acquisition in stages allowing

payment to be spread over time and

matches operational cash flows profile

Value creation

Day one valuation uplift:

•Stage one purchase price of $14m

•Combined asset valuation of $19m

•+0.02 cent (or +15%) uplift to March

2024 NTA per share

17
Transaction structure

and funding

Stage one

Acquisition of:

•Golden View care facility

•Golden View apartments

•Ripponburn facility and village

$14m purchase price with completion and settlement

August 2024

To be funded by way of:

•$7.5m of bank & debt financing

•$3.0m proceeds from asset sales

•$3.5m new equity to be raised

Golden View village leased over for 4-year period

•Vendor receives 40% of ORA net proceeds

•PHL receives 60% of ORA net proceeds

•No rent payable

Stage two

Acquisition of:

•Golden View village and recreational facilities

$19.35m purchase price, completion August 2028

To be funded by way of:

•$6m of convertible notes, issued August 2024

(0% coupon, 50% convertible at holder’s option into

shares at 0.1 cents by August 2025, 50% by August

2028)

•$8.6m of cash (paying $180k monthly from August

2024 over 4 years, effectively a deposit on

consideration)

•$4.7m cash payable August 2028

18
Equity to be raised

•Minimum of $3 million to be raised by way of placement and additional Share Purchase

Plan (SPP)

•Pricing $0.001

•Issue price at a 21% discount to NTA

•Shares to be in all respects equivalent to existing equity, and NZX listed

•For every share subscribed in addition will be attached 1 warrant which can be

exercised up to 24

th

March 2027 at $0.002

•An application will be made to the NZX to get the free attached warrant to be listed as

a separate security

•All Promisia Healthcare Board members to participate

•Discretion to accept $1 million in oversubscriptions

Legal and advisory costs for capital raise are estimated at $0.25m

19
Indicative impact on shareholder register

Top 5 shareholders

All other shareholders

New placement

Share purchase plan

Exercised warrants

Exercised convertible notes

Current Register

1

Post July 24 placement & SPP

2

Following exercise of warrants

and convertible notes

3,4

Key Assumptions:

1

As at 30 June 2024. Total issued capital of 21,516,308,487 ordinary shares.

2

New placement of 3,000,000,000 ordinary shares at $0.001 per share. Assumed uptake of SPP at 500,000,000 ordinary shares at $0.001 per share.

3

Based on assumed August 2024 placement and SPP issuance, 3,500,000,000 warrants to be issued. Graph assumes exercise of all warrants and issuance of

3,500,000,000 of ordinary shares at $0.002 per share.

3

As part of the Cromwell acquisition, $6m of convertible notes to be issued to vendor at option price of $0.001 per share. Graph assumes exercise of all notes and

issuance of 6,000,000,000 of ordinary shares at $0.001 per share.

20
Indicative Financial Position

As at March 2024 ($ ’000)

Assets

Cash and working capital517

Fixed assets (plant & equipment)1,269

Care facilities, villages & land59,825

61,611

Liabilities

Borrowings(29,155)

Revenue received in advance (2,288)

Other liabilities(3,037)

(34,480)

Net Tangible Assets27,131

Deferred tax liabilities

(2,251)

Net Assets / Shareholders Equity24,880

Pro forma position ($ ’000)

Post Cromwell acquisition (August 2024)

1

Assets

Cash and working capital250

Fixed assets (plant & equipment)2,250

Care facilities, villages & land72,325

74,825

Liabilities

Borrowings(33,250)

Revenue received in advance (2,250)

Other liabilities(3,000)

(38,500)

Net Tangible Assets36,325

Deferred tax liabilities

(2,251)

Net Assets / Shareholders Equity34,074

1

Key assumptions: $3.5m of equity raised from new placement & SPP and net

proceeds from asset sales used to repay borrowings.

21
Debt Position and

Loan Covenants

BNZ have offered debt financing for Cromwell, as well

as refinancing of the wider Group.

This offer reflects our strong relationship with BNZ, and

the progress made in executing Promisia’s strategy

and delivering strong operational performance.

Cromwell

$7.5m secured BNZ term loan, conditional on:

•Successful capital raise

•Unconditional agreement for sale of Eileen Mary

Promisia Group

•Refinance of $6.5m Senior Trust loan

•Extension of $6.6m of existing facilities maturing in

October 2024

•Both on a 2-year term and at improved rates

March 2024

Post Cromwell

Transaction

BNZ$18.5m$29.3m

Senior Trust$6.5m-

Teltower$4.0m$4.0m

Total Group Debt$29.0m$33.3m

Villages and Facilities$59.8m$72.3m

LVR (%)

Group48%46%

BNZ31%40%

BNZ LVR covenant: BNZ drawn debt not to exceed 50% of

secured property value.

22
Promisia within the wider aged care sector

•Promisia’s key point of difference is our focus on larger sized aged care facilities, with a

medium to long term investment strategy, focusing on quality and value add

opportunities.

•Initially started with a small base, growing facilities with size and scale in care beds, with a

village component and/or greenfield development opportunities.

•Avoided consolidation and rollups, ensuring all acquisitions were prudent and long-term

investments.

•Our portfolio has the added advantage of being primarily provincially based, with lower

land values enabling a higher return on asset value.

•Investment strategy starting to show full potential. Significant value uplifts across Ranfurly

Manor and Aldwins House, with continued operational momentum to unlock further

value.

23
Proven track record of

creating value

Early 2020: Acquired lease of Aldwins House. Vacant

and undergoing significant refurbishment

December 2020: Refurbishment complete and first

wing opened

March 2022: Purchased freehold for $13m

March 2023: Acquired adjacent properties for growth

and development opportunities

October - March 2024: Development of YPD care

offering, diversifying revenue streams.

June 2024: Resident occupancy over 115 residents

Latest valuation (facilities & adjacent land): $18.1m

Aldwins House Case Study

24
Conclusion

Directors and Management team have shown an ability to materially add significant

shareholder value over the last 4 years, with Ranfurly Manor and Aldwins Road seeing

material valuation increases.

Cromwell is earnings accretive from day 1 and offers an attractive entry pricing into an

otherwise highly sought after, but expensive location of Central Otago.

Cromwell offers two sought after facilities that have strong customer demand and

availability of care staff.

Cromwell offers significant short term development potential at a time when further

development opportunities with Feilding and Aldwins Road are more long dated.

The Directors are all participating in the SPP.

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.